Related Experiment Video

Updated: Jun 22, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

[Structural and functional changes in heart under medical therapy in mental workers having arterial hypertension]

E A Denisova, L L Kirichenko, O P Rushkevich

    Meditsina Truda I Promyshlennaia Ekologiia
    |July 2, 2009
    PubMed

    Insights

    This study evaluated treatments for arterial hypertension, finding that Egiloc and Cardilopin effectively improved heart function in patients with hypertension. Both medications, individually or combined, demonstrated positive structural and functional cardiac changes.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Internal Medicine

    Background:

    • Arterial hypertension (high blood pressure) is a significant risk factor for cardiovascular disease.
    • Understanding the impact of antihypertensive medications on cardiac structure and function is crucial for effective patient management.

    Purpose of the Study:

    • To assess the effects of Egiloc and Cardilopin, individually and in combination, on key cardiac parameters in patients with arterial hypertension.
    • To evaluate the treatment efficiency of these medications over a six-month period.

    Main Methods:

    • The study included 126 patients diagnosed with arterial hypertension (Stage II) and 34 healthy controls.
    • Electrocardiography (ECG) and Echocardiography (EchoCG) were performed at baseline, 3 months, and 6 months post-treatment initiation.
    • Patients received medium-dose therapy with Egiloc, Cardilopin, or a combination thereof.

    Main Results:

    • Treatment with Egiloc, Cardilopin, or their combination led to significant improvements in the main structural and functional parameters of the heart in patients with arterial hypertension.
    • The observed changes indicate enhanced cardiac efficiency and potentially reduced cardiovascular risk.

    Conclusions:

    • Egiloc and Cardilopin are effective in managing arterial hypertension by improving cardiac structural and functional parameters.
    • Combination therapy may offer additional benefits, warranting further investigation into optimal treatment strategies for hypertension.

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Pathophysiology of Cardiac Performance01:29

    Pathophysiology of Cardiac Performance

    Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...